Journal of
eISSN: 2473-0831
Submit manuscript...
Clinical Paper Volume 11 Issue 3
Efficacy and safety of emicizumab in usual clinical practice
Nuria Blazquez Ramos, Jose Antonio Romero Garrido, Carmen Sobrino Jiménez, Cristina Bilbao Gómez Martino, Francisco Gaya Moreno, Itsaso Losantos-García, Victoria Lucia Collada Sánchez, Marta Ayllón Morales, Luis González Del Valle, María Teresa Álvarez Román, Victor Jiménez Yuste, Alicia Herrero Ambrosio, Juana Benedí González
Received: October 30, 2022 | Published: November 11, 2022
Abstract
Emicizumab is a drug approved in 2018, which brings a different mechanism of action to treat hemophilia A with and without inhibitor.
Keywords: antibodies bispecific, blood coagulation factor inhibitors, hemophilia A, hemorrhage, quality of life
©2022 , et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.